Poster: In Vitro Characterization of a Dual Antagonistic Anti-LILRB2/LILRB4 Monoclonal Antibody

Check out our poster on a discovery journey in identifying a dual-antagonistic mAb for an IO check point receptor utilizing Curia proprietary platform technology including PentaMice® for maximum antibody diversity, TunaCHO™ for high yield transient expression, in silico humanization, epitope binning, and hybridoma antibody discovery services. Curia Biologics offers these capabilities as a one-stop shop for your next biologics discovery.

(Click on poster image for access to full document)

Visit this page for a deeper understanding of our Antibody Discovery & Engineering Services.

Supplemental Information:
Whitepaper: Leveraging the immunological diversity of the PentaMice® platform for COVID-19 antibody discovery

Fact Sheet: PentaMice – Own your molecules:Therapeutic antibody discovery

Brochure: TunaCHO℠ Platform for Transient Protein & Antibody Production

Brochure: Introduction to hybridoma technologies for antibody discovery

Brochure: Antibody discovery & engineering services

Webinars:
#102: Discovery of Potent, Functional Antibodies Using Hybridoma & Phage Display Platforms Webinar – YouTube
#111: PentaMice™: A Unique Approach to Achieve Maximum Plasma Titers for Antibody Discovery Webinar – YouTube
#115: LakePharma’s Coronavirus Spike Protein Antibodies Webinar – YouTube